Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Buys 2,082 Shares of Danaher Corporation $DHR

Key Points

• Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in Danaher Corporation by 0.1% in Q2, now owning 1,673,418 shares which represent 2.9% of their portfolio.
• Danaher announced a quarterly dividend of $0.32 per share, with an annualized payout of $1.28 and a dividend yield of 0.6%.
• Analysts have set varying target prices for Danaher, with Deutsche Bank increasing its target to $250 and TD Cowen to $260, both maintaining a "buy" rating.

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 0.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,673,418 shares of the conglomerate's stock after acquiring an additional 2,082 shares during the quarter. Danaher accounts for 2.9% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's portfolio, making the stock its 8th largest holding. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned approximately 0.23% of Danaher worth $330,567,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Bleakley Financial Group LLC boosted its position in shares of Danaher by 36.4% in the second quarter. Bleakley Financial Group LLC now owns 27,938 shares of the conglomerate's stock valued at $5,519,000 after acquiring an additional 7,461 shares during the period. Capital Investment Services of America Inc. boosted its position in shares of Danaher by 0.9% in the second quarter. Capital Investment Services of America Inc. now owns 134,533 shares of the conglomerate's stock valued at $26,576,000 after acquiring an additional 1,242 shares during the period. OLD Point Trust & Financial Services N A boosted its position in shares of Danaher by 24.9% in the second quarter. OLD Point Trust & Financial Services N A now owns 1,406 shares of the conglomerate's stock valued at $278,000 after acquiring an additional 280 shares during the period. Forum Financial Management LP boosted its position in shares of Danaher by 29.8% in the second quarter. Forum Financial Management LP now owns 10,200 shares of the conglomerate's stock valued at $2,015,000 after acquiring an additional 2,340 shares during the period. Finally, Ethic Inc. boosted its position in shares of Danaher by 7.5% in the second quarter. Ethic Inc. now owns 65,613 shares of the conglomerate's stock valued at $13,044,000 after acquiring an additional 4,552 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 11.10% of the company's stock.

Analyst Ratings Changes

DHR has been the subject of several research reports. Robert W. Baird set a $247.00 price objective on Danaher in a research report on Wednesday. Deutsche Bank Aktiengesellschaft raised their target price on Danaher from $235.00 to $250.00 and gave the stock a "buy" rating in a research report on Wednesday. TD Cowen raised their target price on Danaher from $250.00 to $260.00 and gave the stock a "buy" rating in a research report on Wednesday. Redburn Partners set a $220.00 target price on Danaher in a research report on Wednesday, October 8th. Finally, Rothschild Redb cut Danaher from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and a consensus price target of $243.39.

Danaher Stock Down 1.2%

Shares of NYSE DHR opened at $218.06 on Thursday. The stock has a market cap of $156.14 billion, a PE ratio of 44.96, a PEG ratio of 3.20 and a beta of 0.77. The business has a fifty day moving average of $202.24 and a two-hundred day moving average of $197.73. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $260.88. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.93% and a net margin of 14.44%.The company had revenue of $6.05 billion during the quarter, compared to analysts' expectations of $6 billion. During the same period last year, the business earned $1.71 earnings per share. The business's revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher's dividend payout ratio (DPR) is 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.